225 related articles for article (PubMed ID: 16436935)
1. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Fuchs E; Simon M; Schmelting B
Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S17-20. PubMed ID: 16436935
[TBL] [Abstract][Full Text] [Related]
2. The interaction between the internal clock and antidepressant efficacy.
Racagni G; Riva MA; Popoli M
Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
[TBL] [Abstract][Full Text] [Related]
3. Circadian rhythms, melatonin and depression.
Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
[TBL] [Abstract][Full Text] [Related]
4. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
7. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
Guardiola-Lemaitre B; De Bodinat C; Delagrange P; Millan MJ; Munoz C; Mocaër E
Br J Pharmacol; 2014 Aug; 171(15):3604-19. PubMed ID: 24724693
[TBL] [Abstract][Full Text] [Related]
8. The mechanism, efficacy, and tolerability profile of agomelatine.
MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.
Ettaoussi M; Sabaouni A; Pérès B; Landagaray E; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
ChemMedChem; 2013 Nov; 8(11):1830-45. PubMed ID: 24031039
[TBL] [Abstract][Full Text] [Related]
10. Synergistic mechanisms involved in the antidepressant effects of agomelatine.
Tardito D; Molteni R; Popoli M; Racagni G
Eur Neuropsychopharmacol; 2012; 22 Suppl 3():S482-6. PubMed ID: 22867907
[TBL] [Abstract][Full Text] [Related]
11. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
12. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
[TBL] [Abstract][Full Text] [Related]
14. Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Vengeliene V; Noori HR; Spanagel R
Neuropsychopharmacology; 2015 Dec; 40(13):2897-906. PubMed ID: 25994077
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine: efficacy at each phase of antidepressant treatment.
Kennedy SH
CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
[TBL] [Abstract][Full Text] [Related]
16. ACS chemical neuroscience molecule spotlight on Valdoxen.
Hopkins CR
ACS Chem Neurosci; 2010 Dec; 1(12):772-3. PubMed ID: 22778814
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
[TBL] [Abstract][Full Text] [Related]
18. Melatonergic drugs in clinical practice.
Hardeland R; Poeggeler B; Srinivasan V; Trakht I; Pandi-Perumal SR; Cardinali DP
Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
[TBL] [Abstract][Full Text] [Related]
19. Agomelatine, an innovative pharmacological response to unmet needs.
Le Strat Y; Gorwood P
J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
[TBL] [Abstract][Full Text] [Related]
20. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
Bourin M; Prica C
Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
